Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)

Bayer

Status: Completed

Conditions: Pulmonary Hypertension

Treatments: Drug: Iloprost (Ventavis BAYQ6256)

Study type: Observational

Funder types: Industry

Identifiers

NCT01062282

14184

VENIS

VE0610KR

Details and patient eligibility

About

The purpose of this study is to gain information on safety and efficacy from Korean patients who starting Ventavis treatment by observational method.

Enrollment: 41 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The treating physician has chosen Ventavis as a suitable treatment for the patient
• Patient with PH and classified as NYHA functional class III or IV and WHO group 1

Exclusion criteria

• Any condition that prevents participation in the study, including pregnancy and other contraindications for Ventavis treatment (as listed in the current Ventavis patient package insert).

Trial design

41 participants in 1 patient group

Group 1

Treatment:

Drug: Iloprost (Ventavis BAYQ6256)